Develops fatty acid synthase inhibitor drug candidates for people with MASH, acne and select cancers.
10-K for FY2025, filed Mar 11, 2026We are a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target…View ↗
Sagimet focuses on discovering and developing drug candidates and has no sales, marketing or distribution capabilities for approved drugs. In Greater China, Ascletis holds a license to develop, manufacture and commercialize denifanstat; Sagimet intends either to build its own commercial organization or outsource the work if a drug is approved.
10-K for FY2025, filed Mar 11, 2026
10-Q for Q3 FY2026, filed Nov 12, 2026
−$19.1MView ↗
8-K, filed Nov 12, 2026
AURORA Phase 3 clinical trial: In October 2026, Sagimet announced that the first patient had been dosed in its AURORA registrational U.S.…View ↗
8-K, filed Oct 1, 2026
On September 30, 2026, Sagimet Biosciences Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with…View ↗
8-K, filed Aug 13, 2026
On August 13, 2026, Sagimet Biosciences Inc. (the “Company”) announced that the U.S. Food and Drug Administration cleared the…View ↗
Competes with Madrigal Pharmaceuticals, Novo Nordisk, Altimmune, AstraZeneca, Boehringer Ingelheim, Zealand Pharma, Eli Lilly and, Galmed Pharmaceuticals, Gilead Sciences, GSK, Inventiva, Merck &, Pfizer, Roche Holdings, Terns Pharmaceuticals, Viking Therapeutics, and Zydus Therapeutics
10-K for FY2025, filed Mar 11, 2026The biopharmaceutical industry is characterized by intense competition and rapid innovation. Accordingly, our competitors may be able to…View ↗
Loading...